Objective: To report the reasons for discontinuation of contraceptive methods by women with epilepsy (WWE). Methods: These retrospective data come from a web-based survey regarding the contraceptive practices of 1,144 WWE in the community, ages 18-47 years. We determined the frequencies of contraceptive discontinuations and the reasons for discontinuation. We compared risk ratios for rates of discontinuation among contraceptive methods and categories. We used chi-square analysis to test the independence of discontinuation reasons among the various contraceptive methods and categories and when stratified by antiepileptic drug (AED) categories. Results: Nine hundred fifty-nine of 2,393 (40.6%) individual, reversible contraceptive methods were discontinued. One-half (51.8%) of the WWE who discontinued a method discontinued at least two methods. Hormonal contraception was discontinued most often (553/1,091, 50.7%) with a risk ratio of 1.94 (1.54-2.45, p < 0.0001) compared to intrauterine devices (IUDs), the category that was discontinued the least (57/ 227, 25.1%). Among all individual methods, the contraceptive patch was stopped most often (79.7%) and the progestin-IUD was stopped the least (20.1%). The top three reasons for discontinuation among all methods were reliability concerns (13.9%), menstrual problems (13.5%), and increased seizures (8.6%). There were significant differences among discontinuation rates and reasons when stratified by AED category for hormonal contraception but not for any other contraceptive category. Significance: Contraception counseling for WWE should consider the special experience profiles that are unique to this special population on systemic hormonal contraception.
Family planning is an important consideration for women of reproductive age. Selection of an optimal contraceptive method, which is an important component, poses challenges, since almost half of the women who try a reversible contraceptive method discontinue it due to dissatisfaction. 1 Selection of an optimal contraceptive method poses additional challenges for women with epilepsy (WWE) because hormonal contraception (HC), which is used by almost half of the WWE at risk of unintended pregnancy, 2 has interactions with some antiepileptic drugs (AEDs) that may compromise contraceptive efficacy, seizure control, or both. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Although the reasons for discontinuation of contraceptive methods have been reported for women in the general population, 1 reasons may differ for WWE. However, there are no large-scale, community-based studies that report the rates or reasons for discontinuation of contraceptive methods by this special population. Herein we present the findings of the Epilepsy Birth Control Registry (EBCR) survey for the rates and reasons for discontinuation of the various contraceptive methods by WWE in the community and how these findings may differ in relation to the category of AED in use.
Methods

Subjects
The data come from the first 1,144 WWE who participated in the EBCR online survey. Inclusion was limited to 18-to 47-year-old women who reported a diagnosis of epilepsy. Women younger than age 18 were excluded from the survey due to the difficulty in verifying online consent of minors and their guardians. Overall, the EBCR population is younger, better educated, and has fewer minorities compared to the general population. Detailed demographic characteristics of the EBCR population have been published previously. 2 
Standard protocol approvals, registrations, and patient consents
This study was approved by the Western Institutional Review Board as well as the Columbia University Medical Center Institutional Review Board. Online consent was obtained from all participants before taking the survey.
Data collection and definitions
The study was carried out between 2010 and 2014. The survey gathered demographic, epilepsy, AED, and reproductive, as well as contraceptive use and discontinuation data.
Each participant was asked to select which birth control methods she had ever used. The response options included the following: withdrawal, male condom, female condom, combined oral contraceptive pill (combined OCP), progestin-only oral contraceptive pill (progestin-only OCP), depomedroxyprogesterone acetate (DMPA), progestin implant, contraceptive patch, copper intrauterine device (CIUD), progestin intrauterine device (PIUD), vaginal ring, tubal ligation, and partner with vasectomy. The response options also included the generally most frequently used combinations. Withdrawal-condom combination, withdrawal-OCP combination, and condom-OCP combination. For each method selected, the subjects were asked if they had used the method in the last month, if they were having sexual intercourse while using the method, what AEDs they were using while on the method, whether they think their seizure frequency and severity changed while on the method, and if they were currently using the method. Those who stated they were no longer using a method were asked to select all applicable reasons for discontinuation from a list that contained increased seizures, not sexually active, seeking pregnancy, became pregnant on the method, concerns about reliability, concerns about interaction with AEDs, concerns about sexually transmitted infection (STI) safety, trouble remembering to use, difficulty using, inconvenience, tubal ligation or partner with vasectomy, irregular periods, abnormal bleeding, painful periods, headaches, nausea, weight gain, emotional changes, bloating/fluid retention, pelvic pain/discomfort or irritation, insurance, and other. The list of reasons was generated from the most frequently reported unstructured responses during an initial trial period for the survey. This analysis focuses on the reasons for discontinuation of contraceptive methods that would leave WWE at risk of unintended pregnancy and thereby excludes selections of not sexually active or seeking pregnancy.
Categories of reversible contraception were withdrawal, barrier (male and female condom), intrauterine device (IUD, copper and progestin), and hormonal (combined OCP, progestin-only OCP, DMPA, progestin implant, contraceptive patch, and vaginal ring). Subcategories of hormonal contraception included combined (combined OCP, vaginal ring, contraceptive patch), progestin-only (progestin-only OCP, DMPA, progestin implant), oral (combined and progestin-only OCPs), and nonoral (DMPA, progestin implant, contraceptive patch, vaginal ring). Subcategories of IUD were CIUD and PIUD. Categories of contraceptive combinations are nonhormonal combinations (condom-withdrawal combination) and hormonal combinations (condom-OCP combination and withdrawal-OCP combination). Tubal ligation and male vasectomy were not considered reversible methods of contraception.
We categorized AED treatment as none, monotherapy, or polytherapy. AEDs were grouped into six categories based on their effects on enzymatic metabolism: (1) No AED; (2) enzyme-inducing AEDs (EIAEDs), which included phenobarbital, phenytoin, carbamazepine, oxcarbazepine, and topiramate in dosages >200 mg daily; (3) glucuronidated AEDs (GluAEDs), which included only lamotrigine; (4) non-enzyme-inducing AEDs (NEIAEDs), which included levetiracetam, zonisamide, gabapentin, topiramate in
Key Points
• Women with epilepsy (WWE) discontinue 40% of contraceptive methods they try
• Systemic hormonal contraception (50.7%) has a twofold greater rate of discontinuation than intrauterine device (25.1%)
• Nonoral methods are discontinued more often than oral methods and progestin-only methods, more so than combined methods
• The top three reasons for discontinuation among all methods were reliability concerns, menstrual problems, and increased seizures dosages up to 200 mg daily, lacosamide, clobazam, pregabalin, and tiagabine; (5) enzyme-inhibiting AEDs (InhAEDs), which included only valproate; and (6) mixed categories. Note, valproate was listed in the InhAED category, although it is also partially glucuronidated. When there was a combination of a category that affected enzymes and an NEIAED, the combination was listed by the AED category that affected enzymes. If the combination comprised two or more categories that affected enzymes, they were listed as mixed.
Outcomes
We present rates and reasons for discontinuation under four separate classifications: (1) all reversible methods; (2) categories (withdrawal, barrier, hormonal, and IUD); (3) subcategories: hormonal-combined versus progestin and oral versus nonoral, IUD-CIUD versus PIUD, (4) individual methods, and (5) combinations.
Statistical analysis
We report the frequencies of reversible contraceptive methods that the WWE ever used and that were discontinued (SPSS v23). We tested the independence of discontinuation rates and discontinuation reasons by contraceptive categories, subcategories, individual methods, and when stratified by AED using chi-square analysis. We determined risk ratios (RRs) and their 95% confidence intervals (95% CIs) for discontinuation rates and reasons by contraceptive categorizations, and when stratified by AED categories, using the lowest rate or reason for discontinuation as referent. We used RRs and their 95% CIs to compare rates and reasons for discontinuations among categorizations and between the EBCR population and the general population. Contraceptive methods used in combination were analyzed separately. AED stratification did not include the mixed category.
Results
Discontinuation rates
One thousand twenty-nine WWE (89.9%) in the EBCR reported their experiences with the use of 2,396 individual, reversible contraceptive methods; 30.2% of the WWE had used only one individual reversible method, 29.3% used two methods, 24.7% used three, and 15.7% used four or more. A total of 5 participants and 33 methods were excluded from the analysis because they lacked information as to whether methods were discontinued or currently in use (18, 0.75%), or the reasons for discontinuation (15, 0.63%).
Five hundred thirty-three (52.1%) of the 1,024 WWE discontinued 959 (40.6%) of the 2,363 methods. Approximately one-half (51.8%) of the WWE who discontinued a method (27% of WWE who reported contraceptive use in the EBCR overall) discontinued at least two methods.
There was a significant difference in rates of discontinuation by contraceptive categories (v 2 = 94.09, d.f. = 3, p < 0.001). Table 1 presents the breakdown of discontinuation rates by categories and individual methods. Using IUD, the least discontinued category, as referent, the risk for discontinuation of the other contraceptive categories, in increasing order, was as follows: barrier RR = 1.26 (0.98-1.61, p = 0.068), withdrawal RR = 1.47 (1.12-1.91, p = 0.0042), and HC RR = 1.94 (1.54-2.45, p < 0.0001).
Within the HC category, a comparison of subcategories found that nonoral methods were discontinued more often than oral methods (308/692, 44.5% vs. 245/399, 61.4%; RR = 1.38 [1.23-1.54], p < 0.0001) and progestin-only methods were discontinued more often than combined estrogen-progestin methods (169/295, 57.3% vs. 384/796, 48.2%; RR = 1.19 [1.05-1.34], p = 0.0058).
Within the IUD category, using PIUD as referent, the risk for discontinuing CIUD was RR = 1.72 (1.11-2.67, p = 0.0162).
Rates of discontinuation also varied by individual methods (v 2 = 154.47, d.f. = 10, p < 0.001). Figure 1 presents the risks for discontinuation, using PIUD, which had the lowest rate at 20.1%, as referent. Among all individual methods, the contraceptive patch was discontinued most often (47/59, 79.7%). The rates of discontinuation differed significantly for HC when stratified by AED category (v 2 = 39.68, d.f. = 4, p < 0.0001) but not for withdrawal, barrier, or IUD. WWE using NEIAEDs discontinued HC the least (60/179, 33.5%). The frequencies and RRs, using HC + NEIAED as referent, for discontinuing HC when stratified by the various AED categories are presented in Table 2 .
Two hundred ten WWE reported the use of 309 contraceptive combinations. Two hundred six (66.7%) consisted of hormonal combinations; 82 (26.5%) consisted of the barrier-withdrawal nonhormonal combination. The frequencies of each of the remaining 6.8% of the combinations were too low for meaningful statistical analysis; 37.1% (76/206) of the hormonal combinations and 21.2% (17/82) of the nonhormonal combination were discontinued. The risk for discontinuing hormonal combinations compared to the nonhormonal combination was RR = 1.77 (1.12-2.82), p = 0.0139. Among hormonal combinations, there was no significant difference between the risk for discontinuing OCP + condom versus OCP + withdrawal. The rates for discontinuation of hormonal versus nonhormonal combinations when stratified by AED categories yielded small frequencies that did not differ significantly between the two categories of combinations.
Discontinuation reasons
One thousand four hundred forty-seven reasons were given for the 959 discontinued individual methods. The reason most often cited for discontinuation among all of these reversible methods was reliability concern (13.9%) followed in decreasing order by menstrual problems (13.5%), increased seizures (8.6%), concern about interaction with AEDs (7.7%), inconvenience (7.7%), weight gain/bloating (6.4%), pregnant on method (5.6%), discomfort/irritation (5.0%), emotional changes (4.8%), headaches (4.4%), difficulty using (3.6%), trouble remembering to use (3.7%), insurance (2.5%), nausea (2.1%), and other (10.1%, each reason comprising of <1%).
Discontinuation reasons varied by contraceptive categories (v 2 = 717.17, d.f. = 48, p < 0.001). Table 3 presents the top three reasons for discontinuation of each contraceptive category as both a percent of WWE who discontinued the method and a percent of all WWE who ever used the method. Reliability was the most frequent concern on withdrawal (57.5% of reasons), inconvenience on barrier (29.3%), menstrual problems on HC (27.7%), and menstrual problems on IUD (49.1%). Of note, among the perhaps most important reasons, unintended pregnancies occurred with 16.5% of withdrawal practices, whereas increased seizures prompted discontinuation in 19.3% of experiences with HC use.
Discontinuation reasons differed among hormonal subcategories: oral versus nonoral (v 2 = 104.97, d.f. = 16, p < 0.001) and combined versus progestin-only (v 2 = 45.47, d.f. = 16, p < 0.001). The top discontinuation reason for oral methods was interaction with AEDs (88/308, 28.6%), whereas the top reason for nonoral methods was menstrual problems (69/245, 28.2%). The top discontinuation reason for combined estrogen-progestin methods was interaction with AEDs (85/384, 22.1%) and the top reason for progestin-only methods was menstrual problems (52/ 169, 30.8%).
Discontinuation reasons differed among individual contraceptive methods (v 2 = 1057.061, d.f. = 160, p < 0.001). The top three reasons for each method are presented in Table 4 . The individual method with the highest selection of increased seizures as a reason for discontinuation was implanted progestin (6/16, 37.5%); male condom had the lowest (5/205, 2.4%). The risk for discontinuation of each method is presented as a risk ratio (RR) relative to progestin IUD, the method with the lowest risk at 20.1%. PIUD, progestin intrauterine device; CIUD, copper intrauterine device; OCP, oral contraceptive pills; DMPA, depomedroxyprogesterone acetate. Epilepsia ILAE The top three discontinuation reasons for hormonal combinations, in descending order, were menstrual problems (38.5%), concern regarding AED interaction (26.9%), and inconvenience (19.2%). For the nonhormonal combination, reliability (41.2%), inconvenience (31.8%), and discomfort (25.4%) were the top three reasons. Menstrual problems, AED interaction concerns, and increased seizures were unique to hormonal combinations, whereas reliability, inconvenience, and discomfort were common to both hormonal and nonhormonal combinations. Discontinuation for seizure increase was twofold more frequent on hormonal combinations (10/76, 13.2%), than on the nonhormonal combination (1/17, 5.9%), but not significantly so.
The reasons for discontinuation of contraceptive categories differed significantly for HC when stratified by AED categories (v 2 = 132.00, d.f. = 64, p < 0.001) but not for withdrawal, barrier, or IUD. The top reasons for discontinuation of HC when stratified by AED categories are presented in Table 5 as numbers and percentages of the WWE who discontinued the method while using HC and the AED category and all WWE who used HC and the AED category. Among the top three reasons, menstrual problems appeared for all AED categories. Increased seizures was listed among the top three reasons for all categories except EIAED. The rate of discontinuation for seizure increase on HC + EIAED was 13.8% (20/145). Using HC + EIAED as referent, the risks for seizure increase on HC when stratified by AED category are presented in Figure 2 . Of note, 94.7%, that is, 18 of 19, of the discontinuations for seizure increase on No AED occurred while in combination with HC. The reasons for discontinuation of hormonal versus nonhormonal combinations when stratified by AED categories yielded small frequencies that did not differ significantly between the two categories of combinations.
Discussion
More than half of the WWE in the EBCR discontinued a contraceptive method. This rate is greater than the finding in the general population (52.1% [95% CI 48.14-54.26%] vs. 46%). 1 Moreover, a greater percentage of the WWE who discontinued a method, discontinued more than one method in comparison to women in the general population (51.8% [47.56-56.04%] vs. 36.0%). 1 This finding is even more striking when considering that lifetime use of the number of tried contraceptive methods increases with age 15 and that the EBCR population is much younger than the general population 2 and, therefore, should have used and discontinued fewer contraceptive methods. The disparity could result from differences in the methods of ascertainment and selection bias, that is, WWE who have had issues with contraception may be more likely to seek out the EBCR survey, whereas women in the general population were part of a door-to-door survey. The disparity, however, could also indicate that WWE have concerns or complications of contraceptive use that go beyond those of women in the general population and are specific to WWE. This is particularly AED, antiepileptic drug; EIAED, enzyme-inducing AED; GluAED, glucuronidated AED; NEIAED, non-enzyme-inducing AED; InhAED, enzyme-inhibiting AED. N1, WWE who discontinued hormonal contraception when using the AED category; N2, WWE who tried hormonal contraception with the AED category; n1, number of discontinuations (% of all discontinuations of the category) for the reason; n2, number of discontinuations (% of all experiences on the category) for the reason. The risk of discontinuation for increased seizures on each HCÀAED combination is presented as a risk ratio (RR) relative to HC+EIAED, the combination with the lowest risk. HC, systemic hormonal contraception; AED, antiepileptic drug; EIAED, enzymeinducing AED; NEIAED, non-enzyme-inducing AED; GluAED, glucuronidated AED; InhAED, enzyme-inhibiting AED. Epilepsia ILAE apparent for HC, for which two of the top three reasons for discontinuation were unique to WWE. HC, the one contraceptive category that is known to have interactions with some AEDs and has been associated with greater changes in seizure frequency than other categories, 16 was discontinued significantly more often by WWE than by women in the general population (EBCR: 50.7% [47. 8-53.7] vs. 32.1%), whereas IUD, which has been shown to have no interaction with AEDs 17, 18 and has greater efficacy, 19 was discontinued less (25.1% [18.9-31.7] vs. 36.4%). 1 The possibility that WWE warrant special consideration is supported not only by the differences in these rates but also by the finding that AED interaction and increased seizures, issues uniquely relevant to WWE, were among the top three reasons for discontinuation of HC but not for any of the other contraceptive categories.
The special consideration of epilepsy as a factor is further supported by the different rates and reasons for discontinuation of HC when stratified by the various categories of concomitantly used AEDs. The top three reasons for discontinuing HC while on EIAEDs were menstrual problems, concerns about AED interaction, and concerns about reliability. EIAEDs have been shown to reduce serum concentrations of contraceptive steroids significantly and, thereby, could reduce contraceptive efficacy. [3] [4] [5] [6] [7] [8] [9] [10] Lower contraceptive steroid concentrations, especially ethinyl estradiol, might also be an explanation for HC + EIAEDs having the lowest risk of increased seizures. 16 Animal experimental evidence finds that the administration of ethinyl estradiol, a component of combined OCPs, vaginal ring, and contraceptive patch, for 14 days to female mice lowered hippocampal-kindled seizure thresholds and increased seizure severity. 20 GluAEDs (lamotrigine) were discontinued most often due to concerns about interactions with AEDs, followed by increased seizures. Ethinyl estradiol reduces serum lamotrigine levels, sometimes by >50%, and the reduced levels have been associated with increased seizures. [12] [13] [14] InhAED was discontinued mostly for weight gain. Weight gain is a common side effect of valproate. 21 Weight gain also occurs with the use of one form of HC in the general population, DMPA. 22 OCP use in the general population has been associated with an increased percentage of body fat, but weight gain did not differ significantly from nonhormonal contraception use. 22 Increased seizures was the second most common reason for discontinuing HC + InhAED. This HCÀAED combination has been found to have the greatest risk for increased seizures in the EBCR population. 16 Combined OCPs lower valproate levels, likely by the induction of glucuronidation, 11 and valproate may raise ethinyl estradiol levels, which could have an added proconvulsant effect. 16, 20, 23, 24 NEIAED + HC was the least discontinued HCÀAED combination, albeit still 33.5%. NEIAEDs have shown no pharmacokinetic interactions with contraceptive hormones. 25, 26 The combination had no significant risk for increased seizures compared to HC + No AED or HC + EIAED, which had the lowest risk. Increased seizures, the third most common discontinuation reason overall, could be a result of the HC itself. 16, 24 The finding that 94.7% of discontinuations on No AED occurred while on HC is consistent.
Both withdrawal and barrier categories had significantly higher rates of discontinuation in the EBCR than in the general population ( 1 Reliability concerns were among the top three reasons for both withdrawal and barrier categories. These categories have a much higher failure rate for typical use in the general population compared to all other methods (withdrawal 22%, female condom 21%, male condom 18%) 19 and WWE, who have a higher rate of congenital malformations, [27] [28] [29] could be more concerned about unintended pregnancy than those in the general population. Only 13.2% of male condom users in the general population discontinued the method as their sole method of contraception due to concerns about reliability 1 compared to 21.5% in the EBCR population.
IUD had the lowest discontinuation rate (25.1% [19.8-30.8] ) in the EBCR. The rate was significantly lower than that reported in the general population (36.4%).
1 Pilot studies find that PIUD use does not have a significant effect on serum AED levels, and the risk of unintended pregnancy is not increased when combined with the use of enzyme inducing drugs. 17, 18 AED interaction is the top reason listed for selection of any contraceptive method by WWE. 2 The second most common reason for selection was efficacy, 2 and both types of IUDs (CIUD, PIUD) have two of the three lowest failure rates among reversible methods of contraception. 19, 30 Among those who did discontinue an IUD, the reasons were not unique to the epilepsy population. Menstrual problem was the most frequent reason cited for CIUD, whereas menstrual problem and pelvic discomfort were the reasons most often cited for PIUD, consistent with the most common discontinuation reasons for IUDs in the general population. 31 As in the general population in whom headaches are reported to occur in 16.3% with PIUD but not CIUD use, 32, 33 headache was a reason that was reported with PIUD (4/43, 9.3%) but not CIUD (0/38, 0.0%) in the EBCR population, thereby raising an interesting question about the possible role of the hormonal component of the PIUD.
Conclusions
The finding that most WWE discontinue contraceptive methods for reasons that would leave them at risk of unintended pregnancy focuses attention on the potentially avoidable health and economic consequences of less than optimal selection of contraception in this special population. The finding highlights the need for prospective investigation of the issue in order to generate guidelines and promote counseling regarding the selection of optimal forms of contraception for and by WWE. Guidelines must consider the special concerns that WWE have regarding (1) efficacy in the setting of a higher risk for having offspring with congenital malformations, (2) hormonal interactions with AEDs, and (3) hormonal effects on seizures. Advocacy needs to consider that age, race/ethnicity, and insurance are significant predictors of access to highly effective forms of contraception, and that only a minority of WWE consult their neurologist regarding selection of a method, although AED interaction is cited as the top reason for selection. 2 
